TABLE 3. Lung function and tomographic abnormalities present in COVID-19 survivors two months after hospital discharge from Hospital Universitário Clementino Fraga Filho.
|
Variable |
Two-month assessment n/N (%)a |
|---|---|
|
Lung function tests |
|
|
Total of patients |
73 |
|
Time from discharge to LFT, days | |
|
Median (IQR) |
75 (62–91) |
|
Lung function abnormalities, n/N (%) |
|
|
Obstructive pattern |
10/69 (14.5%) |
|
Restrictive pattern |
7/65 (10.8%) |
|
Reduced DLCO |
22/63 (34.9%) |
|
Small airway disease (IOS) |
20/66 (30.3%) |
|
Chest CT |
|
|
Total of patients |
77 |
|
Time from discharge to CT, days | |
|
Median (IQR) |
75 (60.5–92.5) |
|
Tomographic evolution, n/N (%) |
|
|
Complete resolution |
19/73 (26.0%) |
|
Partial resolution |
54/73 (74.0%) |
|
Unchanged |
0/73 (0%) |
|
Progression |
0/73 (0%) |
|
Tomographic abnormalities, n/N (%) |
|
|
Architectural distortion |
47/77 (61.0%) |
|
Ground-glass opacities |
42/77 (54.5%) |
|
Peripheral reticulation |
37/77 (48.1%) |
|
Traction bronchiectasis |
33/77 (42.9%) |
|
Parenchymal bands |
32/77 (41.6%) |
|
Septal thickening |
31/77 (40.3%) |
|
Emphysema |
21/77 (27.3%) |
|
Bronchial wall thickening |
14/77 (18.2%) |
|
Consolidation |
6/77 (7.8%) |
|
Crazy-paving |
3/77 (3.9%) |
|
Honeycombing |
1/77 (1.3%) |
Notes: LFT, lung function test; IQR, interquartile range; CT, computed tomography; DLCO, diffusing lung capacity for carbon monoxide; IOS, impulse oscillometry.
N refers to the total number of patients evaluated, and n refers to the number of patients with abnormal results.
Source: Prepared by the authors from the study results.